SCHEMBL5200468

SCHEMBL5200468

COCC(C)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2627432 1.00
SCHEMBL4545489 1.00
Hydrochloric Acid SCHEMBL4701396 0.97
SCHEMBL23901198 0.89 SCN4A (0.35)
SCHEMBL26033404 0.86 SCN4A (0.32)
SCHEMBL24908212 0.86 SCN4A (0.32)
SCHEMBL16826803 0.80 CA2 (0.34)
SCHEMBL473650 0.79
SCHEMBL11242156 0.79 SCN4A (0.39)
SCHEMBL20207458 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117936901-A Rechargeable magnesium battery amine electrolyte and preparation method and application thereof 上海交通大学 2024-04-26 CN claimed
US-20260042757-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 VENTUS THERAPEUTICS U S INC (US) 2026-02-12 US disclosed
EP-4320102-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 VENTUS THERAPEUTICS U S INC (US) 2026-01-14 EP disclosed
US-12441728-B2 Pyridazine compounds for inhibiting NLRP3 VENTUS THERAPEUTICS U.S., INC. (US) 2025-10-14 US disclosed
US-12410167-B2 Pyridazine compounds for inhibiting NLRP3 VENTUS THERAPEUTICS U.S., INC. (US) 2025-09-09 US disclosed
US-20250250270-A1 COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2025-08-07 US disclosed
US-12351578-B2 Compounds for inhibiting NLRP3 and uses thereof VENTUS THERAPEUTICS U.S., INC. (US) 2025-07-08 US disclosed
US-12312350-B2 Compounds for inhibiting NLRP3 and uses thereof VENTUS THERAPEUTICS U.S., INC. (US) 2025-05-27 US disclosed
US-12281112-B2 Compounds for inhibiting NLRP3 and uses thereof VENTUS THERAPEUTICS U.S., INC. (US) 2025-04-22 US disclosed
EP-4537900-A2 COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-04-16 EP disclosed
US-20120263670-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2012-10-18 US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed
WO-2011145957-A1 AGENTS AND METHODS FOR DETECTION AND/OR IMAGING OF HYPOXIA AUCKLAND UNISERVICES LIMITED (NZ) 2011-11-24 WO disclosed
US-8063058-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-22 US disclosed
US-20110196014-A1 METHIONINE ANALOGS AND METHODS OF USING SAME BIOXINESS PHARMACEUTICALS, INC. (CA) 2011-08-11 US disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 US disclosed
EP-1817309-A1 ACETAMIDE COMPOUNDS AS FUNGICIDES Syngeta Participations AG (CH) 2007-08-15 EP disclosed
WO-2006058700-A1 ACETAMIDE COMPOUNDS AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2006-06-08 WO disclosed
US-4049661-A FIBER-REACTIVE CIBA-GEIGY AG (CH) 1977-09-20 US disclosed